Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2009.23.8980 on July 20 2009

Journal of Clinical Oncology, Vol 27, No 24 (August 20), 2009: pp. e74
© 2009 American Society of Clinical Oncology.

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Google Scholar
Right arrow Articles by Crew, K.
Right arrow Articles by Hershman, D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crew, K.
Right arrow Articles by Hershman, D.
Related Articles
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

CORRESPONDENCE

Reply to R.T. Chlebowski

Katherine Crew, Dawn Hershman

Columbia University Medical Center, New York, NY

We would like to thank Chlebowski1 for elaborating on the uncertainty regarding the benefits of vitamin D in women with breast cancer. As was elegantly outlined in the editorial by Goodwin,2 the number of articles related to vitamin D has increased substantially over the past 20 years, and uncertainty still exists regarding the risks associated with vitamin D deficiency, as well as the possible benefits associated with supplementation.3

We would like to clarify that the main objective of our study was to describe the prevalence of vitamin D deficiency (defined as serum 25-hydroxyvitamin D [25(OH)D] < 20 ng/mL) in a cohort of premenopausal women with newly diagnosed breast cancer. In doing that we found that not only was vitamin D deficiency present in over 70% of women at study entry, but also that standard supplementation with 400 U daily of vitamin D3 over 1 year only had a slight impact on the rate of vitamin D deficiency.

We recognize, and state as such, that given the current evidence, it would be premature to recommend vitamin D supplementation to all patients with breast cancer and that the optimal level of serum 25(OH)D in this patient population is still unknown. However, as we suggest, and as was reiterated by Goodwin,2 it might be prudent to check levels and monitor supplementation rather than endorsing a fixed dose for all patients,4 given that many experts recommend repletion of vitamin D to sufficient levels.5

The increasing interest and biologic rationale justify continued research in the area of cancer prevention and treatment. Ongoing clinical trials may help clarify whether changing a woman's vitamin D status will alter her risk of breast cancer or, for those who develop breast cancer, whether it will alter the risk of breast cancer recurrence and improve survival.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

REFERENCES

1. Chlebowski RT: Caution regarding 25-hydroxyvitamin D monitoring in women with breast cancer. J Clin Oncol 27:e72–e73, 2009.[Free Full Text]

2. Goodwin PJ: Vitamin D in cancer patients: Above all, do no harm. J Clin Oncol 27:2117–2119, 2009.[Free Full Text]

3. Cui Y, Rohan TE: Vitamin D, calcium, and breast cancer risk: A review. Cancer Epidemiol Biomarkers Prev 15:1427–1437, 2006.[Abstract/Free Full Text]

4. Crew KD, Shane E, Cremers S, McMahon DJ, et al: High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 27:2151–2156, 2009.[Abstract/Free Full Text]

5. Holick MF: Vitamin D deficiency. N Engl J Med 357:266–281, 2007.[Free Full Text]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

  • Caution Regarding 25-Hydroxyvitamin D Monitoring in Women With Breast Cancer
    Rowan T. Chlebowski
    JCO 2009 27: 72-73 [Full Text]



This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Google Scholar
Right arrow Articles by Crew, K.
Right arrow Articles by Hershman, D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crew, K.
Right arrow Articles by Hershman, D.
Related Articles
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online